前沿生物跌2.03%，成交额1.42亿元，主力资金净流出328.91万元

Group 1 - The core viewpoint of the news is that Frontier Biopharmaceuticals has experienced significant stock price fluctuations, with a year-to-date increase of 53.59% but a recent decline of 15.41% over the past five trading days [1] - As of September 9, the stock price of Frontier Biopharmaceuticals was reported at 14.99 yuan per share, with a total market capitalization of 5.615 billion yuan [1] - The company has seen a net outflow of main funds amounting to 3.2891 million yuan, with large orders showing a buy of 26.5552 million yuan and a sell of 27.5182 million yuan [1] Group 2 - Frontier Biopharmaceuticals, established on January 15, 2013, and listed on October 28, 2020, focuses on the research, development, production, and sales of innovative drugs addressing significant unmet clinical needs [2] - The company has one patented anti-HIV drug on the market and two drugs in clinical trials, showcasing its strong capabilities in long-acting peptide drug development [2] - As of June 30, the number of shareholders increased by 5.74% to 12,000, while the average circulating shares per person decreased by 5.43% to 31,095 shares [2] Group 3 - For the first half of 2025, Frontier Biopharmaceuticals reported an operating income of 58.6398 million yuan, reflecting a year-on-year growth of 14.85%, while the net profit attributable to the parent company was -97.3526 million yuan, an increase of 39.33% year-on-year [2]